Healthcare Industry News: HSMN NewsFeed
News Release - July 7, 2020
BD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin PreparationNew BD PurPrep™ skin preparation is the only commercially available PVP-I antiseptic skin preparation with sterile solution in the U.S.
FRANKLIN LAKES, N.J., July 7, 2020 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of BD PurPrep™ patient preoperative skin preparation with sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation (PVP-I; 0.83% available iodine and 72.5% isopropyl alcohol) commercially available in the United States.
BD PurPrep™ joins BD ChloraPrep™ patient preoperative skin preparation as the only fully sterile skin preparations available on the market that use a single-use applicator specifically designed to prevent cross-contamination and promote aseptic non-touch technique. The BD PurPrep™ patient preoperative skin preparation is an effective skin preparation alternative when the use of a chlorhexidine gluconate (CHG/IPA) is contraindicated or the patient is sensitive to CHG.
"Though progress has been made, health care-associated infections remain a problem," said Donald E. Fry, M.D., a nationally recognized expert in infection prevention. "Sterile single-use products have been shown to reduce the risk of outbreaks linked to microbial contamination of antiseptic products. By developing fully sterile PurPrep and ChloraPrep, BD is providing health care professionals with a more complete set of tools to reduce the risk of intrinsic contamination in antiseptic solutions."
The new BD PurPrep™ formulation includes a fluid-resistant, film-forming polymer developed to facilitate drape adhesion and help create a durable antimicrobial barrier1,2 that helps iodine bind to the skin for residual antimicrobial activity. In an irrigation study, mimicking real-world clinical practice, BD PurPrep™ patient preoperative skin preparation with sterile solution remained on the skin immediately following a saline challenge.2
"BD PurPrep strengthens our commitment to health care professionals and patients by providing an alternative fully sterile option to help reduce the risk of intrinsic contamination," said Michael Cusack, BD, Vice President/General Manager of Infection Prevention. "By adding a non-CHG, fully sterile skin preparation option, BD is expanding the number of tools available to help reduce the risk of infection in patients with CHG sensitivities and during procedures when CHG/IPA is not indicated."
BD PurPrep™ will replace Prevail™ and Prevail FX™, and is available now through BD and other distribution partners.
Novel Sterilization Process
BD's proprietary sterilization process was designed to achieve a minimum sterility assurance level (SAL) of 10-6, the same level required for injectable products.1 The SAL indicates there is less than one in 1 million chance that a sterile BD PurPrep™ or BD ChloraPrep™ applicator containing sterile solution will contain a single, viable microorganism following terminal sterilization of the ampoules through BD's new sterilization process.1 While a product labeled as non-sterile does not suggest that it is contaminated with bacteria, it indicates that the contents have not been sterilized individually.
Like BD ChloraPrep™, the new BD PurPrep™ sterile solution will include a mark to indicate that the solution is sterile. Though not required by the U.S. Food and Drug Administration (FDA), BD developed this mark to distinguish sterile solutions from non-sterile antiseptic skin preparations. In 2013, the FDA asked manufacturers to voluntarily change labeling on products (sterile vs. non-sterile) to further educate customers on the issue.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. For more information on BD, please visit bd.com.
1 Jeng, D. A new, water-resistant, film-forming, 30-second, one-step application iodophor preoperative skin preparation. Am J Infect Control. 2001, 29(6):370-376
2 Mashiatulla, M. (2020). Iodine-based Pre-Operative Skin Preparation Product Performance on Porcine Abdominal Skin. Internal BD report: unpublished.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBD Acquires the Medical Business Assets of CUBEX LLC, Broadening Automated Dispensing Portfolio Across Care Continuum
BD Announces Executive Leadership Appointments
BD Granted FDA 510(k) Clearance for BD FACSLyric(TM) Flow Cytometer with Newly Integrated BD FACSDuet(TM) Sample Preparation System